

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 73589

**Title:** Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: a case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 02505244

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Italy

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-12-06

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-12-06 20:33

**Reviewer performed review:** 2021-12-13 12:54

**Review time:** 6 Days and 16 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	---

#### **SPECIFIC COMMENTS TO AUTHORS**

Novel interesting case report; the authors should cite the following recent paper regarding the presented specific clinical issue entitled: "Current imaging evaluation of tumor response to advanced medical treatment in metastatic renal-cell carcinoma: Clinical implications" by Caruso M, et al. Applied Sciences 2021; 11 (15) 6930; DOI 10.3390/app11156930.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 73589

**Title:** Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: a case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05449164

**Position:** Peer Reviewer

**Academic degree:** MDS

**Professional title:** Medical Assistant

**Reviewer's Country/Territory:** Peru

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-12-06

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-01-06 21:01

**Reviewer performed review:** 2022-01-10 20:02

**Review time:** 3 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No
-------------------------------------	---

## SPECIFIC COMMENTS TO AUTHORS

I consider that the paper is publishable in the World Journal of Clinical Cases after a major revision, especially in discussion part. I am pleased to suggest this manuscript for publication in the journal if the above suggestions are incorporated and the paper is thoroughly edited. In addition, I made some suggestions in order to correct or incorporate in the manuscript:

1. Section MULTIDISCIPLINARY EXPERT CONSULTATION: I consider that it is not necessary to specify the departments and hospitals in which the patient was treated. Please summarize them in a paragraph that follows the sequence of the medical history.
2. Section FINAL DIAGNOSIS: Please add the patient's risk according IMDC score.
3. The patient was treated with Apatinib since April 2021; however, in the Figure 3 Is the patient's progression to TKI seen, have you considered start with immunotherapy? (Nivolumab)